Abdulrafeh Naqash to Antibodies, Monoclonal, Humanized
This is a "connection" page, showing publications Abdulrafeh Naqash has written about Antibodies, Monoclonal, Humanized.
Connection Strength
1.534
-
Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition. J Immunother Cancer. 2019 07 05; 7(1):169.
Score: 0.616
-
Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series. J Immunother Cancer. 2019 01 08; 7(1):4.
Score: 0.595
-
Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade. J Oncol Pharm Pract. 2019 Apr; 25(3):551-557.
Score: 0.138
-
Interleukin-6 as one of the potential mediators of immune-related adverse events in non-small cell lung cancer patients treated with immune checkpoint blockade: evidence from a case report. Acta Oncol. 2018 05; 57(5):705-708.
Score: 0.138
-
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study. Hepatology. 2022 10; 76(4):1000-1012.
Score: 0.047